Skip to main content

Alzheimer's Webinar Series Part 1: Neuroradiology Practice: Getting Ready for Alzheimer Drugs

Alzheimer's Webinar Series Part 1: Neuroradiology Practice: Getting Ready for Alzheimer Drugs

Description & Learning Objectives
Required for Inclusion in the ASNR Directory of ARIA-Education Practitioners and presented by the ASNR Alzheimer's/ARIA/Dementia Study Group

Upon completion of this activity, participants will gain strategies to:
-Understand the role of beta amyloid In both Alzheimer's disease and cerebral amyloid angiopathy;
-Describe the etiology of therapeutically induced amyloid related imaging abnormalities;
-Describe imaging findings of amyloid related imaging abnormalities;
-Understand implications of possible approval of disease modifying interventions for Alzheimer's disease;
-Gain an appreciation of preparations needed to accommodate introduction of disease modifying interventions for Alzheimer's disease in clinical practice.
Instructions for Participation
To complete this activity, learners will watch a recording of a live webinar and submit a course evaluation. Once all elements are completed, a certificate will be automatically added to your transcript.
Credit Dates
Available: 5/12/2021
Expires: 5/11/2024

To add your name to the Directory of ARIA-Educated Practitioners by completing the required webinars, please visit the DIRECTORY REQUIREMENTS PAGE.

Planners & Faculty
Tammie Benzinger, MD, Moderator
Clifford Jack, MD, Speaker
Vijay Ramanan, MD, PhD, Speaker

Accreditation Statement
The American Society of Neuroradiology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Neuroradiology designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In compliance with ACCME requirements and guidelines, ASNR has developed a policy for disclosure and review of potential conflicts of interest and a method for resolution if a conflict does exist. ASNR maintains a tradition of scientific integrity and objectivity in its educational activities. In order to preserve these values and ensure its educational activities are independent and free of commercial bias, all individuals, including planners, presenters, moderators and evaluators, participating in an ASNR educational activity, or an activity jointly provided by ASNR must disclose all relevant financial relationships with ineligible companies, as defined by the ACCME. Unless listed below, all planners and individuals in control of content have nothing to disclose.

Dr. Benzinger has received investigator initiated research funding from the NIH, the Alzheimer's Association, the Barnes-Jewish Hospital Foundation and Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly) Dr. Benzinger participates as an investigator in clinical trials sponsored by Avid Radiopharmaceuticals, Eli Lilly, Biogen, Eisai, Jaansen, and Roche and serves as a consultant to Biogen, Eisai and Siemens.

All other participants and planners have no disclosures.

This series is generously supported by an unrestricted educational grant from Icometrix and Biogen.
Other Resources